Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 Rapid Letter

Bracing for impact with new 4R's in the COVID-19 pandemic – A provincial thoracic radiation oncology consensus

Shrinivas Rathod a,⇑, Arbind Dubey a, Bashir Bashir a, Gokulan Sivananthan b, Ahmet Leylek a, Amitava Chowdhury a, Rashmi Koul a

aCancerCare Manitoba and University of Manitoba, Winnipeg; and bWestern Manitoba Cancer Center, Brandon, Manitoba, Canada

Abstract

As COVID-19 pandemic continues to explode, cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic radiation regimen in a Canadian province with 4 new R's of COVID era.

Introduction

The world and health care system is scrambling as COVID-19 pandemic continues to explode [1]. As of 24th March 2020, over 400,000 cases are reported worldwide and the numbers keep rising constantly [1]. Apart from the Arctic, it has engulfed every continent and country. With this unimaginable scenario, the healthcare system in the entire world is under immense pressure and struggling to cope.

Available data shows COVID-19 carries high risk or morbidity and mortality for elderly and immuno-compromised individuals [2]. Reports from China show Cancer patients have an aggressive course and carry a 3.5 higher risk of mortality [3]. The study also found patients with cancer deteriorated more rapidly than those without cancer (median time to severe events 13 days vs 43 days) [3].

Cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Hospitals are designing new policy measures and working hard to implement those in place. Radiation Oncology is an integral part of oncology care and the nature of fractionated treatment requires patients to visit cancer centers daily for a significant number of days. The risk of patient contacting/getting exposed to COVID-19 and diffusion of spread is paramount [4]. The risk of decrease in specialized radiation oncology workforce could hamper and even halt operations of radiation oncology centers [5]. Learning from Chinese and Italian experience, aiming to reduce the impact of epidemic operations changes several are recommended [4,6,7].

Radiation oncology community must evaluate options of prioritizing radiation treatments (RT), deferring where applicable, omitting where there is no or very minimal benefit and strongly consider reduce numbers of fractions where there is evidence to support [8].

We proposed 4 new R's in the COVID era [1] ViRtual care (reduce in-person consult/follow up/on treatment visits) [2] Ration radiation (offer radiation wisely and avoid RT where minimal benefit) [3] defeR radiation (as appropriate) [4] hypofRactionate radiation (where applicable) and came up with provincial preferred thoracic radiation regimen.

Several measures are adopted by Canadian physicians such as virtual care to minimize in-person clinic visits and deferral where needed. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic hypofractionated radiation regimen in our provincial cancer center.

Methods

CancerCare Manitoba provides comprehensive oncology services for the province of Manitoba and adjacent areas of
Northwestern Ontario and Nunavut. Approximately 3500 new patients are seen/treated annually including approximately 600–650 new lung cancer patients. We are a modern radiation oncology department with 8 modern linear accelerators including True beam and Edge machines and using IGRT, rapid arc and SRS/SBRT techniques in our standard clinical practice.

With provincial emergency declarations, Thoracic Radiation oncology (RO) group was tasked with disease specific COVID-19 emergency preparedness plan. Our Team reviewed the current evidence to assess the role and available options of different radiation regimens in the management of lung cancers. We assessed different common scenarios where radiation would be treated and prioritized the indications. Priority levels were assigned based on prognosis and the expected benefit of radiation treatment. Curative treatments, where delay/deferral would jeopardize the survival outcomes, were considered as a high priority. Treatment indications for symptomatic measures or consolidation (treatment gains in quality of life or progression-free survival) were considered as an intermediate priority. Treatment indications where the role of radiation is debatable (no significant overall survival impact or other options as observation were appropriate) were considered as low priority. Thoracic RO team attained consensus and recommended evidence-based preferred hypofractionated radiation regimen for clinical care at our provincial comprehensive cancer center.

Recommendations

Non-small cell Lung Cancers:
Stage I-II NSCLC:
- Priority level – high:
  - RO Consensus: Stage I-II (node negative) NSCLC represents a curative scenario and nonsurgical candidates with good performance status should undergo stereotactic body radiation treatment. Peripheral tumours should be treated with 54 Gy in 3 fractions (FR) and preferred over 48 Gy in 4 Fr option [9,10]. We do not practice 30–34 Gy in 1 fraction at our center yet, however once available could be preferred for appropriate patients [10]. Central tumours should be treated with 50 Gy in 5 Fr as a preferred option [11]. Group discouraged use of 60 Gy in 8 Fr for central tumours. However, this would be considered a valid option for the treatment of ultra-central tumours. The use of hypofractionated regimen as 60 Gy in 15 Fr is not preferred unless the patient is not a candidate for SBRT [12].
- Stage II (node positive) – III NSCLC:
  - Priority level – high:
    - RO Consensus: Group agreed inoperable stage II (node positive) – III population with good performance status would be best served with curative concurrent chemo radiation with standard doses of 60 Gy in 30 Fr [13]. Our group did not support concurrent chemo and hypofractionated radiation options. We discouraged the use of a longer regimen such as 66 Gy in 33 Fr at present [13]. We recommended candidates ineligible for concurrent chemo radiation should receive sequential chemoradiation (if suitable) with hypofractionated radiation as 55 Gy in 20 Fr or 40 Gy in 15 Fr.
  - Stage IV NSCLC:
    - Priority level – Intermediate:
      - RO Consensus: Majority stage IV NSCLC patients face significant symptom burden. Palliative radiation offers a significant improvement in symptoms and Quality of life [14]. Group recommended 8–10 Gy in 1 Fr or 16 Gy in 2 Fr (1 week apart) as preferred regimen over other fractionated regimen as 20 Gy in 5 Fr or 30 Gy in 10 Fr especially in patients with poor performance status [15]. There is no strong evidence that any regimen gives greater palliation [16].

Small-cell Lung Cancers:
Limited stage (stage I–III):
- Priority level – high:
  - RO Consensus: Concurrent chemo radiation plays a vital role in the management of this curative group of patients. We adopted 40 Gy in 15 Fr as a preferred consensus recommendation for good performance status candidates [17]. Group discouraged use of 45 Gy in 30 Fr BID or 66 Gy in 33 Fr regimens in the current scenario [18,19]. The evidence suggests early administration of concurrent RT is superior to delayed administration and RO favoured early administration of RT [20].
  - Stage I SCLC could account for 10% of screen detected lung cancers. Acknowledging the limitations of available data, SBRT should be considered in stage I SCLC [21,22]. In such cases group favored SBRT should be offered post chemotherapy [23].
  - Palliative cranial radiation:
    - Priority level – Intermediate:
      - RO Consensus: For palliative stage SCLC responding to initial therapy, our group supported and recommended standard regimen of PCI (25 Gy in 10 Fr) for eligible patients [24].
  - Extensive stage (stage III–IV):
    - Consolidation thoracic radiation:
      - Priority level – Intermediate:
        - RO Consensus: For extensive stage SCLC responding to initial therapy, consolidation thoracic radiation improves progression-free survival; reduces intra-thoracic failures, however, does not improve overall survival significantly. For suitable patients group favored 20 Gy in 5 Fr over other regimens [25,26].
  - Palliative cranial radiation:
    - Priority level – Low:
      - RO Consensus: For extensive stage SCLC responding to initial therapy, the role of PCI is debatable [27,28]. For eligible patients group supported and recommended MRI surveillance as a preferred option in the current environment [27,28].

Fig. 1. Priority pyramid. SBRT – stereotactic body radiation treatment, RT – radiation, CT – chemotherapy, NSCLC – non small cell lung cancer, SCLC– small cell lung cancer.
men are shown in Fig. 1 and Table 1 respectively.

**Discussion**

With the current pandemic and associated restrictions, we believe this preferred RT regimen will serve as a policy document for the thoracic radiation community (Table 1 and Fig. 1). The model of virtual care (reduce in-person consult/follow upon treatment visits), ration radiation (offer radiation wisely and avoid RT where minimal benefit), defer radiation (as appropriate), hypofractionate radiation (where applicable) are emerging as new 4R’s of radiation therapy.

These measures will be helpful to minimize patient visits to radiation centers and reduce the risk of patient exposure to infection. The preferred hypofractionated regimen may help minimize the impact of COVID19 on in these unprecedented and unfortunate times. We are hopeful these measures will help mitigate the impact of COVID-19 pandemic on our patients and cancer centers.

**Conclusion**

In the current times, 4 new R’s of Radiation treatment will help mitigate the impact of COVID-19 pandemic on our patients and cancer centers.

**Conflict of interest**

None to disclose.

**References**

[1] https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
[2] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020.
[3] Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335–7.
[4] Filippi AR, Russi E, Magrini SM, et al. Covid-19 outbreak in Northern Italy: first practical indications for radiotherapy departments. Int J Radiat Oncol Biol Phys 2020.
[5] Rivera AON, Thomas E, Miller R, Knoll MA, et al. Impact of COVID-19 on radiation oncology clinics and cancer patients in the U.S. Adv Radiat Oncol 2020.
[6] Krenig MFE, Mastroleo F, Brambilla M, Ricardi U. Running a Radiation Oncology Department at the time of coronavirus: an Italian experience. Adv Radiat Oncol 2020.
[7] Simcock R, Mercy CE, Filippi AR, Katz MA, Pereira IIJ, Saeed H. COVID-19: Global Radiation Oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol 2020.
[8] Achard V, Tsoutsou P, Zilli T. Radiotherapy in the time of the Coronavirus pandemic: when less is better. Int J Radiat Oncol Biol Phys 2020.
[9] Timmerman RD, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial. JAMA Oncol 2018;4:1263–6.
[10] Videtic GM, Paulus R, Singh AK, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2019;103:1077–84.
[11] Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. J Clin Oncol 2019;37:1316–25.
[12] Swaminath A, Wierzbicki M, Parpia S, et al. Canadian phase III randomized trial of stereotactic body radiotherapy versus conventionally hypofractionated radiotherapy for stage I medically inoperable non-small cell lung cancer: rationale and protocol design for the Ontario Clinical Oncology Group (OCOG): LUSTRE trial. Clin Lung Cancer 2017;18:250–40.
[13] Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: standard versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol 2020;38:705–14.
[14] Rathod S, Jeremy B, Fidariova E, et al. Quality of life outcomes in a phase 3 randomized trial of optimization of treatment of advanced non-small cell lung cancer using radiation therapy and chemotherapy: IAEA multicentric randomized phase 3 study (NCT00864331). Int J Radiat Oncol Biol Phys 2017;99:S103.
[15] Rodrigues G, Videtic GM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol 2011;1:60–71.
[16] Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev 2015;1:CD002143.
[17] Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336–44.
[18] Faire-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017;18:1116–25.
[19] Turrisi 3rd AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited-stage small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–71.
[20] De Ryuscher D, Lueza B, Le Pechoux C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol 2016;27:1818–28.
[21] Rathi S, Koul R, Bashir B, et al. Role of stereotactic body radiation therapy in early stage small cell lung cancer in the era of lung cancer screening: a systematic review. Am J Clin Oncol 2019;42:123–30.
[22] NCCN Guidelines – small cell lung cancer. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf (assessed on 29th March 2020).
[23] Stahl JM, Corso CD, Verma V, et al. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer 2017;103:11–6.

[24] Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99–01, EORTC 22003–08004, RTOG 0212, and IFCT 99–01): a randomised clinical trial. Lancet Oncol 2009;10:467–74.

[25] Rathod S, Jeremic B, Dubey A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer 2019;110:110–9.

[26] Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015;385:36–42.

[27] Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:663–71.

[28] Slotman B, Faire-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664–72.